Lukas Biomedical (ROCO:6814) Short-Term Debt: NT$126.9 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6814 Lukas Biomedical Inc ROCO:6814
66 GF Score
Price NT$21.50
GF Value NT$21.00
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Lukas Biomedical Short-Term Debt?

Lukas Biomedical ROCO:6814 -3.59% 66 Short-Term Debt is NT$126.9 Mil as of Jun. 2026. GuruFocus rates ROCO:6814 with a GF Score™ of 66/100 and a GF Value™ of NT$21.00 (Fairly Valued). The stock has 8 warning signs investors should review.

Lukas Biomedical's Short-Term Debt for the quarter that ended in Jun. 2026 was NT$126.9 Mil.

Lukas Biomedical's quarterly Short-Term Debt increased from Jun. 2025 (NT$46.6 Mil) to Dec. 2025 (NT$76.7 Mil) and increased from Dec. 2025 (NT$76.7 Mil) to Jun. 2026 (NT$126.9 Mil).

Lukas Biomedical's annual Short-Term Debt declined from Dec. 2023 (NT$12.7 Mil) to Dec. 2024 (NT$11.4 Mil) but then increased from Dec. 2024 (NT$11.4 Mil) to Dec. 2025 (NT$76.7 Mil).

Lukas Biomedical Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Lukas Biomedical Short-Term Debt Related Terms

Lukas Biomedical Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Lukas Biomedical's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lukas Biomedical Short-Term Debt Chart

Lukas Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 96.55 6.37 12.65 11.44 76.73

Lukas Biomedical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.14 11.44 46.59 76.73 126.86
ROCO:6814
66GF Score
Lukas Biomedical Inc ROCO:6814
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of NT$126.9 Mil mean?
Lukas Biomedical (ROCO:6814) has a Short-Term Debt of NT$126.9 Mil as of Jun. 2026.
Is Lukas Biomedical's Short-Term Debt too high?
Lukas Biomedical's current Short-Term Debt is NT$126.9 Mil. Overall, Lukas Biomedical has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lukas Biomedical's Short-Term Debt compare to VRTX and REGN?
Lukas Biomedical's Short-Term Debt of NT$126.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Lukas Biomedical's current Short-Term Debt is NT$126.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lukas Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lukas Biomedical (ROCO:6814) is currently considered Fairly Valued. The stock's GF Value™ is NT$21.00, compared to a current price of NT$21.50 — trading 2.4% above its estimated fair value. The current Short-Term Debt is NT$126.9 Mil. Lukas Biomedical's overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Lukas Biomedical (ROCO:6814), the current Short-Term Debt is NT$126.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lukas Biomedical (ROCO:6814) Overvalued in 2026?

Based on GuruFocus' analysis, Lukas Biomedical stock appears to be overvalued. The current stock price of NT$21.50 is trading 2.4% above its estimated GF Value™ of NT$21.00. GuruFocus considers Lukas Biomedical to be Fairly Valued.

Key valuation signals for ROCO:6814:

  • Short-Term Debt: NT$126.9 Mil
  • GF Value™: NT$21.00 vs. price of NT$21.50 (2.4% above fair value)
  • GF Score™: 66/100 with 8 warning signs

No single metric tells the full story. See the ROCO:6814 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lukas Biomedical Business Description

Address No. 14-16, Zhongxiao Road, 1st Floor, Banqiao District, New Taipei City, TWN, 220
Lukas Biomedical Inc. is engaged in researching and developing immunotherapy for cancer treatment technologies. The company's main business activities include developing immunocellular therapy, leasing and selling medical equipment, and selling biotech beauty products.
66GF Score

Get the complete analysis for ROCO:6814

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$21.50
Price
NT$21.00
GF Value